Therapeutic Efficacy and Biomarker of Allergen Immunotherapy

DOI Web Site Web Site 6 References

Bibliographic Information

Other Title
  • アレルゲン免疫療法の効果とバイオマーカー
  • アレルゲン メンエキ リョウホウ ノ コウカ ト バイオマーカー

Search this article

Description

<p>The prevalence of allergic rhinitis, especially that of Japanese cedar pollinosis, has increased in recent years in Japan. Furthermore, spontaneous remission of Japanese cedar pollinosis is rare until old age. Allergen immunotherapy (AIT) is currently considered to be the only effective therapy with the potential to alter the natural course of allergic rhinitis. In many placebo-controlled clinical trials of AIT for allergic rhinitis, significant improvements of symptoms have been observed in the AIT group as compared to the placebo group. Regular allergen administrations over a period of years are needed to obtain stable long-term efficacy of AIT; however, some patients still show poor efficacy. Therefore, if the therapeutic efficacy could be predicted at an early time point of the treatment, the burden of non-responders would be reduced. There are no generally accepted predictive biomarkers until date, however, it would be desirable to identify a biomarker for predicting the therapeutic efficacy of AIT and evaluate its usefulness in clinical settings.</p>

Journal

References(6)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top